Recently, in vivo stable 211At-labeled PSMA derivatives using astatobenzene structures have been developed that have high tumor growth suppression and low side effects in normal tissues (Mease et al. 2022; Fakiri et al. 2024). Here, FOLH1 is linked to neoplasm.